Thus, AZD8186 can effectively reduce growth of SETD2 mutant tumors but not SETD2 wild-type tumors, underscoring the importance of the molecular connection between the PI3Kβ signaling network and SETD2 loss as a promising therapeutic target for ccRCC. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.